Pataday Once Daily Relief Patent Expiration

PATADAY ONCE DAILY RELIEF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5641805 ALCON LABS INC Topical ophthalmic formulations for treating allergic eye diseases
Jun, 2015

(9 years ago)

US5641805

(Pediatric)

ALCON LABS INC Topical ophthalmic formulations for treating allergic eye diseases
Dec, 2015

(8 years ago)

US7402609 ALCON LABS INC Olopatadine formulations for topical administration
Jun, 2022

(2 years ago)

US7402609

(Pediatric)

ALCON LABS INC Olopatadine formulations for topical administration
Dec, 2022

(1 year, 6 months ago)

US6995186 ALCON LABS INC Olopatadine formulations for topical administration
Nov, 2023

(8 months ago)

US6995186

(Pediatric)

ALCON LABS INC Olopatadine formulations for topical administration
May, 2024

(2 months ago)

US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(7 years from now)



Pataday Once Daily Relief is a drug owned by Alcon Laboratories Inc. It is used for treating allergic conjunctivitis and relieving ocular itching associated with allergic conjunctivitis. Pataday Once Daily Relief uses Olopatadine Hydrochloride as an active ingredient. Pataday Once Daily Relief was launched by Alcon Labs Inc in 2004. It is is available in solution/drops form for ophthalmic use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be May 19, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 December, 2004

Treatment: Method of treating allergic conjunctivitis; Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's drug patent expiration?
More Information on Dosage

PATADAY ONCE DAILY RELIEF family patents

Family Patents